These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

309 related articles for article (PubMed ID: 26210103)

  • 61. Genomic portfolio of Merkel cell carcinoma as determined by comprehensive genomic profiling: implications for targeted therapeutics.
    Cohen PR; Tomson BN; Elkin SK; Marchlik E; Carter JL; Kurzrock R
    Oncotarget; 2016 Apr; 7(17):23454-67. PubMed ID: 26981779
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Prostate cancer molecular profiling: the Achilles heel for the implementation of precision medicine.
    Oliveira-Barros EG; Nicolau-Neto P; Da Costa NM; Pinto LFR; Palumbo A; Nasciutti LE
    Cell Biol Int; 2017 Nov; 41(11):1239-1245. PubMed ID: 28477422
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Personalization of prostate cancer therapy through phosphoproteomics.
    Yang W; Freeman MR; Kyprianou N
    Nat Rev Urol; 2018 Aug; 15(8):483-497. PubMed ID: 29752463
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Prospective Genomic Profiling of Prostate Cancer Across Disease States Reveals Germline and Somatic Alterations That May Affect Clinical Decision Making.
    Abida W; Armenia J; Gopalan A; Brennan R; Walsh M; Barron D; Danila D; Rathkopf D; Morris M; Slovin S; McLaughlin B; Curtis K; Hyman DM; Durack JC; Solomon SB; Arcila ME; Zehir A; Syed A; Gao J; Chakravarty D; Vargas HA; Robson ME; Joseph V; Offit K; Donoghue MTA; Abeshouse AA; Kundra R; Heins ZJ; Penson AV; Harris C; Taylor BS; Ladanyi M; Mandelker D; Zhang L; Reuter VE; Kantoff PW; Solit DB; Berger MF; Sawyers CL; Schultz N; Scher HI
    JCO Precis Oncol; 2017 Jul; 2017():. PubMed ID: 28825054
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Triple Aberrant Prostate Cancer (TAPC) - Aggregate role of aberrations in
    Watson AP; Shabaneh A; Wang J; Dehm SM; Rao A; Ryan CJ
    Am J Clin Exp Urol; 2020; 8(4):106-115. PubMed ID: 32929406
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Emerging therapeutic targets for patients with advanced prostate cancer.
    Saad F; Shore N; Zhang T; Sharma S; Cho HK; Jacobs IA
    Cancer Treat Rev; 2019 Jun; 76():1-9. PubMed ID: 30913454
    [TBL] [Abstract][Full Text] [Related]  

  • 67. [The Clinical Utility of Liquid Biopsies as Biomarkers in Metastatic Prostate Cancer].
    Sumiyoshi T; Akamatsu S
    Gan To Kagaku Ryoho; 2021 Oct; 48(10):1203-1208. PubMed ID: 34657048
    [TBL] [Abstract][Full Text] [Related]  

  • 68. What have we learned from exceptional tumour responses?: Review and perspectives.
    Mehra N; Lorente D; de Bono JS
    Curr Opin Oncol; 2015 May; 27(3):267-75. PubMed ID: 25811347
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Genomic Aberrations Drive Clonal Evolution of Neuroendocrine Tumors.
    Kaushik AK; Sreekumar A
    Trends Endocrinol Metab; 2016 May; 27(5):242-244. PubMed ID: 27037211
    [TBL] [Abstract][Full Text] [Related]  

  • 70. The resounding effect of DNA repair deficiency in prostate cancer.
    Cheng HH
    Urol Oncol; 2018 Aug; 36(8):385-388. PubMed ID: 29555412
    [TBL] [Abstract][Full Text] [Related]  

  • 71. The Open University's first one-day symposium on treatment-emergent neuroendocrine prostate cancer.
    Mather RL; Andrews H; Pandha H; Jachetti E; Micallef J; Wang Y; Crea F
    Future Oncol; 2020 Feb; 16(6):147-149. PubMed ID: 31964195
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Metastatic castration resistant prostate cancer with squamous cell, small cell, and sarcomatoid elements-a clinicopathologic and genomic sequencing-based discussion.
    Weindorf SC; Taylor AS; Kumar-Sinha C; Robinson D; Wu YM; Cao X; Spratt DE; Kim MM; Lagstein A; Chinnaiyan AM; Mehra R
    Med Oncol; 2019 Feb; 36(3):27. PubMed ID: 30712214
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Molecular classification of hormone-sensitive and castration-resistant prostate cancer, using nonnegative matrix factorization molecular subtyping of primary and metastatic specimens.
    Yuen KC; Tran B; Anton A; Hamidi H; Costello AJ; Corcoran NM; Lawrentschuk N; Rainey N; Semira MCG; Gibbs P; Mariathasan S; Sandhu S; Kadel EE
    Prostate; 2022 Jun; 82(9):993-1002. PubMed ID: 35435276
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Genomic predictors for treatment of late stage prostate cancer.
    Shevrin DH
    Asian J Androl; 2016; 18(4):586-91. PubMed ID: 27030083
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Genomic Profiling of Prostate Cancer: An Updated Review.
    Hatano K; Nonomura N
    World J Mens Health; 2022 Jul; 40(3):368-379. PubMed ID: 34448375
    [TBL] [Abstract][Full Text] [Related]  

  • 76. High-risk prostate cancer: a disease of genomic instability.
    Tapia-Laliena MA; Korzeniewski N; Hohenfellner M; Duensing S
    Urol Oncol; 2014 Nov; 32(8):1101-7. PubMed ID: 24931269
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Commentary on "Integrative clinical genomics of advanced prostate cancer". Robinson D, Van Allen EM, Wu YM, Schultz N, Lonigro RJ, Mosquera JM, Montgomery B, Taplin ME, Pritchard CC, Attard G, Beltran H, Abida W, Bradley RK, Vinson J, Cao X, Vats P, Kunju LP, Hussain M, Feng FY, Tomlins SA, Cooney KA, Smith DC, Brennan C, Siddiqui J, Mehra R, Chen Y, Rathkopf DE, Morris MJ, Solomon SB, Durack JC, Reuter VE, Gopalan A, Gao J, Loda M, Lis RT, Bowden M, Balk SP, Gaviola G, Sougnez C, Gupta M, Yu EY, Mostaghel EA, Cheng HH, Mulcahy H, True LD, Plymate SR, Dvinge H, Ferraldeschi R, Flohr P, Miranda S, Zafeiriou Z, Tunariu N, Mateo J, Perez-Lopez R, Demichelis F, Robinson BD, Schiffman M, Nanus DM, Tagawa ST, Sigaras A, Eng KW, Elemento O, Sboner A, Heath EI, Scher HI, Pienta KJ, Kantoff P, de Bono JS, Rubin MA, Nelson PS, Garraway LA, Sawyers CL, Chinnaiyan AM.Cell. 21 May 2015;161(5):1215-1228.
    Freedland SJ; Aronson WJ
    Urol Oncol; 2017 Aug; 35(8):535. PubMed ID: 28623072
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Genomic Profiles of De Novo High- and Low-Volume Metastatic Prostate Cancer: Results From a 2-Stage Feasibility and Prevalence Study in the STAMPEDE Trial.
    Gilson C; Ingleby F; Gilbert DC; Parry MA; Atako NB; Ali A; Hoyle A; Clarke NW; Gannon M; Wanstall C; Brawley C; Mason MD; Malik Z; Simmons A; Loehr A; Parry-Jones A; Eeles R; Kote-Jarai Z; James ND; Amos C; Parmar MKB; Langley RE; Sydes MR; Attard G; Chowdhury S;
    JCO Precis Oncol; 2020 Nov; 4():882-897. PubMed ID: 35050761
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Prostate cancer research: The next generation; report from the 2019 Coffey-Holden Prostate Cancer Academy Meeting.
    Miyahira AK; Sharp A; Ellis L; Jones J; Kaochar S; Larman HB; Quigley DA; Ye H; Simons JW; Pienta KJ; Soule HR
    Prostate; 2020 Feb; 80(2):113-132. PubMed ID: 31825540
    [TBL] [Abstract][Full Text] [Related]  

  • 80. The 28th Annual Prostate Cancer Foundation Scientific Retreat report.
    Miyahira AK; Soule HR
    Prostate; 2022 Oct; 82(14):1346-1377. PubMed ID: 35852016
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.